(A) Oncogene mutations were grouped together when they occurred within a given gene (e.g., 'KRAS' for all mutations in 'KRAS') or in the same functional domain of the encoded protein (e.g ...

The drug is designed to inhibit several oncogenic KRAS mutations, which are prevalent in various human cancers. Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion, expressed enthusiasm ...

KRAS genes belong to the class of genes called oncogenes. When an oncogene is mutated, it has the potential to cause cancer. In the early 1980s, scientists identified the first human oncogenes.

Problems arise, however, when mutations convert the proto-oncogene to an oncogene, rendering Ras permanently active regardless of the signals the cell receives. How do tumor suppressors differ?

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Alterome Therapeutics announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors.

We discovered one of the major ways by which RAS oncogenes cause normal cells to become cancerous – and identified new targets for cancer treatment. Scientists at The Institute of Cancer Research led ...

Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This is an ASCO Meeting ...